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Snake venom is a complex mixture of numerous bioactive 
components, mainly proteins and peptides that contribute to 
subdue, kill and/or digest the prey1-5. Composition of the most 
snake venoms counts with about 30% or more of 
metalloproteases (SVMPs), thus pointing to their significant role 
in the envenomation-related pathogenesis, such as bleeding, 
coagulopathies, edema, inflammation and necrosis1,3,5,6.  
SVMPs are responsible for local and systemic hemorrhage. 
This process is an extremely rapid event in vivo, with capillary 
endothelial cells showing drastic structural alterations just within 
few minutes6,7. Because of the difficulty in neutralizing or locally 
inhibiting the action of SVMPs by antivenoms, the search for 
specific inhibitors may represent a new alternative or an add in 
treatment of envenomations7,8.  
Some synthetic substances like O-phenathroline, EDTA8,9 and 
Batimastat, because of their ability to chelate metals (Zn2+ ion in 
the case of SVMP) have been shown to inhibit local hemorrhage 
induced by the venom of Bothrops asper, were tested. It was 
demonstrated that these compounds were effective at inhibiting 
both the isolated SVMPs and the hemorrhagic activity of crude 
venoms in animal models9,10. Also, some hydroxamate-
containing tripeptides with sequence Phe-Leu-Phe showed good 
results in vitro10,11. Although hydroxamates are often pointed out 
as very potent SVMPs inhibitors, several challenges need to be 
addressed in the context of producing new drugs for these 
enzymes. First, their relatively low selectivity is a definite 
problem, which may cause several adverse effects. As broad-
spectrum inhibitors, hydroxamates lead to musculoskeletal 
syndrome side effects, mainly due to the presence of hydroxamic 
acid. By proposing inhibitors with more specific activity against 
the SVMPs some of the low-selectivity associated problems can 
be solved. But still, research has been so far focused mainly on 
highly efficient Zn2+ ion binding groups11,12. Pharmacokinetics 
and toxicological issues of the potential inhibitors represent other 
problems that should be considered in the design of specific 
SVMPs inhibitors. Hydroxamic acids may hydrolyze to the 
corresponding carboxylic acids under physiological conditions. 
Some hydroxamates are prone to hydrolysis in plasma. This 






Snakebites represent an important public health problem, with a great number of 
victims with permanent sequelae or fatal outcomes, particularly in rural, agriculturally 
active areas. The snake venom metalloproteases (SVMPs) are the principal proteins 
responsible for some clinically-relevant effects, such as local and systemic 
hemorrhage, dermonecrosis, and myonecrosis. Because of the difficulties in 
neutralizing them rapidly and locally by antivenoms, the search and design of small 
molecules as inhibitors of SVMPs are proposed. The Bothrops asper metalloprotease 
P1 (BaP1) is hereby used as a target protein and by High Throughput Virtual 
Screening (HTVS) approach, the free access virtual libraries: ZINC, PubChem and 
ChEMBL, were searched for potent small molecule inhibitors. Results from the 
aforementioned approaches provided strong evidences on the structural requirements 
for the efficient BaP1 inhibition such as the presence of the pyrimidine-2,4,6-trione 
moiety. The two proposed compounds have also shown excellent results in performed 
in vitro interaction studies against BaP1.   
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influences their distribution and efficiency because the 
corresponding carboxylic acids are generally less active. 
Hydrolysis may also contribute to the toxicity of the compounds 
because of the fact that the byproduct, hydroxylamine12-14, have 
been shown to have mutagenic characteristics13-15. Thus, the 
inability of hydroxamates to be used as clinically viable 
compounds against SVMPs has been attributed to above noted 
effects. In addition, the public access to metalloprotease 
inhibitors, designed by the pharmaceutical industry, is limited. 
In order to find potential inhibitors to the BaP1 enzyme, a 
structure-based virtual screening (SBVS) campaign was 
conducted on a library constructed from the public databases 
ZINC12 (Drug-Like subset), ChEMBL_17 and PubChem 
(known inhibitors for metalloproteases). The final compound 
library was designed considering molecules containing only 
organic atom types (H, C, N, O, P, S, F, Cl, Br and I). Since 
starting ligand structures can decisively impact on the virtual 
screening results15-17, each library entry was prepared using the 
protocol “Prepared Ligand” as implemented in Discovery Studio 
(DS) version 4.0 (BIOVIA/Accelrys Inc., San Diego, CA, USA) 
with default parameters. This protocol performs tasks such as 
removing duplicates, enumerating isomers and tautomers, and 
generating viable 3D conformations. 
The crystal structure of the BaP1 enzyme was retrieved from 
the Protein Data Bank (PDB: 2W14). More precisely, this PDB 
file describes a structure of the BaP1 enzyme in complex with a 
peptidomimetic inhibitor with very high resolution (1.08 Å). This 
structure was later prepared in order to delete alternate 
conformations (disorder), remove water molecules and ligands 
(except the Zn2+ ion), and finally protonate titratable residues 
using predicted pKas at pH 7.4. All these tasks were performed 
using “Prepare Protein” protocol available in DS 4.0 with default 
parameters. Employing STING's16-19 Java Protein Dossier18-20, 
structural analysis of the prepared enzyme allowed the 
characterization of BaP1’s active site, including the zinc(II) 
coordination site and the deep hydrophobic pocket located at the 
S1´subsite. This pocket was later refined using the module 
“Define Site - From Receptor Cavities" from DS 4.0. 
Considering the amino acid residues that compose the 
peptidomimetic inhibitor binding site on the BaP1 enzyme, a 
structure-based pharmacophore model was built using Ludi 
algorithm as implemented in DS 4.0. Ludi creates a 
pharmacophore model by identifying potential interactions sites 
(features), which can be classified as hydrogen bond donors 
(HBD), hydrogen bond acceptors (HBA) and hydrophobic (HY). 
Because of the importance of the zinc(II) coordination site, the 
obtained pharmacophore model was customized to also 
characterize zinc(II) interaction features regarding the following 
functional groups: carboxyl, phosphate, imidazole, 1,2,3-triazole, 
1,2,4-triazole, tetrazole, thiadiazole, 1-hydroxy-2-oxo 
derivatives20,21. 
Once the compound library, pharmacophore model and target 
enzyme were validated, a SBVS campaign consisting of five 
steps was carried out. Firstly, a fast pharmacophore-based 
screening was performed in order to prioritize compounds 
containing functional groups that can bind to zinc(II). In the 
second step, using LibDock21,22, filtered compounds were docked 
into a region corresponding to the binding site of the co-
crystalized ligand described in the 2W14.pdb. Then, aiming to 
find ligands with high specificity and affinity to the BaP1 
enzyme, successfully docked compounds in step two were 
revaluated considering also the spatial region delimited by the 
highly hydrophobic S1  ´ subsite tunnel. For that, a second 
docking round was performed using LigandFit a shape-based 
molecular docking program suitable for well-characterized 
pocket regions22-24. In step 4, a consensus scoring procedure was 
employed to rank the compounds in terms of binding affinity. 
Affinity metrics calculated at the three previous steps were 
combined into a single scoring function, thus allowing 
identifying compounds that were well evaluated through the 
entire screening process. More precisely, for each of the 
considered metrics, compounds were listed in descending order 
of predicted binding affinity. The consensus score of a given 
molecule was then defined by the number of times it had been 
ranked at the top binding affinity percentile (top 20%). 
Consensus score approaches balance errors in single affinity 
predictions, thus improving the probability of identifying ‘true’ 
ligands23-25. 
The fifth step consisted of a re-ranking procedure. The top 500 
compounds were re-docked using CDOCKER, a CHARMm-
based molecular dynamics (MD) docking program. Considering 
the re-docking results, compounds were then analyzed in terms of 
protein ligand-interactions, being discarded the non-satisfactory 
ones. Finally, the compounds were re-ranked in ascending order 
of CDOCKER energy, which is calculated based on the internal 
ligand strain energy and the protein-ligand interaction energy 
(data organized in Table S1 in Supplementary material section). 
After the SBVS campaign was completed, the five best 
compounds in terms of CDOCKER energy were assayed for 
inhibition of BaP1's proteolytic activity in experiments 
performed in vitro. From those, only two showed inhibition in 
vitro evaluation: ZINC06812429 and ZINC08767570 (from now 
on referred as compounds A1 and A2, respectively).   
In order to shed some light on the binding modes of 
compounds A1 and A2, a quantum and molecular mechanical 
(QM/MM) docking approach (see Supplementary Material) was 
performed. Figure 1 depicts a comparison between the co-
crystallized peptidomimetic inhibitor (PDB: 2W14) and QM/MM 
docking predicted binding modes for the compounds A1 and A2. 
Figure 1 Enlarged view of the molecular interactions of three compounds 
with the BaP1 metalloprotease (PDB: 2W14). (A, C): The co-crystallized 
peptidomimetic inhibitor (carbon atoms colored in orange). (B, D): In silico 
binding modes for compounds A1 (carbon atoms colored in cyan) and A2 
(carbon atoms colored in green), both with the pyrimidine-2,4,6- trione ring 
and placed within the catalytic enzyme site (parts of the molecular structures 
of A1 and A2 overlap). Catalytical zinc ion is shown as a magenta sphere. 
Zinc-coordinating histidines side chains are shown as light gray sticks. BaP1 
subsites are denoted with black bold letters on the molecular surface (only at 
C and D). Figure generated using PyMOL. 
  
         Based on the in silico results, one may suggest that the 
binding of the pyrimidine-2,4,6-trione ring into the catalytic 
BaP1 site S1 occurs through the keto groups of the ligands 
differently of what was shown for some barbiturate-metal 
complexes25,26 that presented tautomeric (enol) forms before 
bonding with the metal. Crystal structure of MMp-9 and mmP-13 
had shown that the N-3 atom of the pyrimidine-2,4,6-trione 
ring is in close contact with the catalytic zinc ion and the oxygen 
atoms O-2 and O-4 belong to  the second coordination shell27,28. 
The docking solutions also showed these coordination modes. 
Also, favorable interactions of ligands (A1 and A2) with the 
BaP1 are established with the His142, His146 and Arg110 
residues that are present in the subsite S1. Other hydrophobic 
interactions with Leu170, Ser168, Gly109, Thr107 and Ile108 
occur principally in subsite S1 (see Supplementary Material, 
Figure S3).  
 
Figure 2 (A) SDS-PAGE (12%) results: Samples as fractions collected from 
the two-step purification of BaP1 were run on 12% gel, and stained with 
Coomassie Brilliant Blue. The protein marker is given at right in kDa (LMW-
SDS Marker kit, Amersham Bioscience). (B) Circular dichroism spectrum of 
BaP1 protein (4 µmol·L-1, Tris-HCl 25 mmol·L-1, pH 8). (C) BaP1 (PDB: 
2W14) carton representation with illustration of secondary structure elements: 
α-helix (in blue), β-sheet (in yellow) and random coil (in green). (D) Circular 
dichroism data at 222 nm during the heating of the BaP1 protein (25-80 ºC 
and 10 ºC/h) showed that BaP1 has a melting point at 52 ºC.   
 
The target SVMP enzyme BaP1 was isolated from the venom 
of Bothrops asper as described by Gutiérrez et al.26,29 and 
Watanabe et al.29,30. A combination of ion-exchange 
chromatography on CM-Sepharose, followed by affinity 
chromatography on Affi-gel Blue for the enzyme BaP1 
purification was employed. Gel electrophoresis (SDS-PAGE, 
12%) was used for protein detection and Circular Dichroism for 
accessing the protein secondary structure features as illustrated in 
Figure 2. The BaP1 showed to be folded protein, with one third 
of its structure being folded as α-helix, as β-sheet or presented 
itself in random coil, thus corroborating with the 3D PDB 
structure features (Figure 2B). Also, BaP1 exhibited the 
relatively high melting point with the Tm at 52 ºC, but was not 
stable thermally as it was not possible to refold it after heating 
protein sample up to 80 ºC.  
The inhibition of proteolytic activity of the BaP1 with the 
docked ligands A1 and A2, was assayed by following the 
cleavage of azocaseine (1 mmol·dm-3), a nonspecific protease 
substrate30. Almost complete inhibition of the proteolytic activity 
of the BaP1 was obtained by both compounds A1 (98% of 
inhibition) and A2 (95% inhibition) in concentrations of 100 
µmol·dm-3 as presented in Table 1. Also using the same 
substrate, IC50 were determined as 20 µmol·dm-3 for A1 and 17 
µmol·dm-3 for A2. 
Table 1 Results for in vitro inhibition30-35 of BaP1’s proteolytic activity over 
azocasein at 1 mmol·dm-3: 
Symbol Compound IC50 
µmol·dm-3  
Inhibition in vitro  
 % 
A1 ZINC06812429  20 ± 2 98 
A2 ZINC08767570 17 ± 2 95 
The BaP1-A1 and BaP1-A2 protein-ligand interactions were 
monitored in vitro and analyzed by applying the fluorescence 
quenching experiments (Figure 3). These enabled us to evaluate 
changes in the environment of the BaP1 tryptophan residues 
when A1 or A2 compounds were present. Both compounds, A1 
and A2 caused quenching in fluorescence when compared with 
the intrinsic fluorescence of the BaP1 protein. In addition, it was 
observed that the maximums of fluorescence were shifted to the 
red region. In the case of the compound A1 this shift was around 
∆ = + 11 nm, and in the case of A2, the shift in Λmax was ∆ = + 7 
nm. 
Figure 3 Fluorescence spectroscopy interaction studies: (A) spectra of BaP1 
(2 µmol·L-1, Tris-HCl 25 mmol· L-1, pH 8.0) free and in the presence of 
inhibitors: BaP1-A1 () or BaP1-A2 (- - -), (B) BaP1 protein carton 
representation (PDB: 2W14) with illustration of its tryptophan (Trp, W) 
residues in red, and (C) Stock-Volmer graphs and Kd constants obtained from 
fluorescence quenching studies for the two pairs BaP1-A1 and BaP1-A2 were 
37.1 and 33.6 µmol.dm−3, respectively. The experiments were repeated three 
times, and plot is showing mean values with error bars. 
The obtained results of the in vitro assays confirmed that 
compounds A1 and A2 are viable BaP1 inhibitors (Table 1 and 
Figure 3). The Stock-Volmer Kd constants obtained from the 
fluorescence quenching studies were 37.1 (BaP1-A1) and 33.6 
µmol.dm-3 (BaP1-A2), together with the inhibition of BaP1 
activity of almost 100% during in vitro experiments make the 
pyrimidine-2,4,6-trione structure moiety very interesting for 
further investigation aimed to improve its binding and affinity 
properties against BaP1. Also, when compared with the known 
peptidomimetic inhibitor31 (Fig. 1. B and D), we can say that the 
  
compounds A1 and A2 exhibited similar IC50 values of around 20  
µmol·dm-3 and when compared to other type of inhibitors32, even 
had lower IC50 and performed an excellent inhibition of BaP1 
proteolytic activity against azocasein.   
Results obtained are not very surprising and are in agreement 
with some previous studies32-37, as one pyrimidine-2,4,6-trione 
has been reported as a promising effective and selective inhibitor 
of cell matrix metalloproteases38,39. Other studies have also 
shown the efficiency of pyrimidine-2,4,6-trione derivatives, 
particularly  one named RO 28-2653 developed by Hoffman-La 
Roche research group, in anticancer therapy33-37. Nevertheless, 
none of the two presented compounds (A1 and A2) have ever 
been pointed as an SVMP BaP1 inhibitors or been used in the 
neutralization of snake venom enzymes. 
      In summary, this study proposes two commercially available 
compounds, A1 and A2 with pyrimidine-2,4,6-trione ring, as new 
inhibitors of the snake venom metalloprotease BaP1. In addition, 
BaP1 protein subsites important for the interaction with the A1 
and A2 were identified. The in vitro tests showed that A1 and A2 
can inhibit the activity of the BaP1 by 95-98%, thus indicating 
that have potential for the development of novel snake venom 
metalloprotease inhibitors. We expect that the results presented 
herein can motivate future efforts in finding potent pyrimidine-
2,4,6-trione derivatives that can be used for SVMPs inhibition in 
vivo.    
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